Skip to main content

Virus Diseases

14
Pipeline Programs
6
Companies
13
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
6
0
1
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
250%
Vaccine
250%
+ 21 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
11 programs
2
4
1
4
Blood drawPhase 4
Encepur AdultsPhase 4
RabipurPhase 4
Valaciclovir HydrochloridePhase 4
RabipurPhase 3
+6 more programs
Syneos Health
Syneos HealthNC - Morrisville
3 programs
1
2
20 micrograms dose H5 VLPPhase 21 trial
Low dose of H5 VLP vaccine + AlhydrogelPhase 2Vaccine1 trial
Low dose of H7 VLP vaccine + AlhydrogelPhase 1Vaccine1 trial
Active Trials
NCT02022163Completed100Est. Dec 2014
NCT01244867Completed255Est. Sep 2011
NCT01991561Completed390Est. Nov 2014
GSK
GSKLONDON, United Kingdom
7 programs
1 µg CoV2 SAMPHASE_11 trial
GlaxoSmithKlinePHASE_21 trial
RabipurPHASE_31 trial
Blood drawPHASE_41 trial
Encepur AdultsPHASE_41 trial
+2 more programs
Active Trials
NCT04758962Completed40Est. Apr 2022
NCT02548078Completed600Est. May 2017
NCT02545517Completed459Est. Dec 2022
+4 more trials
Plus Therapeutics
2 programs
Exposed to a SARS-CoV-2 infectionN/A1 trial
Exposed to a SARS-CoV-2 infectionN/A1 trial
Active Trials
NCT05606198CompletedEst. Jun 2023
NCT05074953CompletedEst. Dec 2023
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
Switch NRTIs as a Backbone to RaltegravirN/ASmall Molecule
MSD
MSDIreland - Ballydine
1 program
Switch NRTIs as a Backbone to RaltegravirN/ASmall Molecule1 trial
Active Trials
NCT00749580Completed46Est. Jul 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKRabipur
GSKEncepur Adults
GSKBlood draw
GSKValaciclovir Hydrochloride
GSKRabipur
GSKGlaxoSmithKline
Syneos HealthLow dose of H5 VLP vaccine + Alhydrogel
Syneos Health20 micrograms dose H5 VLP
GSK1 µg CoV2 SAM
Syneos HealthLow dose of H7 VLP vaccine + Alhydrogel
Plus TherapeuticsExposed to a SARS-CoV-2 infection
Plus TherapeuticsExposed to a SARS-CoV-2 infection
MSDSwitch NRTIs as a Backbone to Raltegravir

Clinical Trials (13)

Total enrollment: 2,252 patients across 13 trials

NCT03192371GSKRabipur

A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children

Start: Feb 2018Est. completion: May 20190
Phase 4Withdrawn
NCT03294135GSKEncepur Adults

The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine

Start: Oct 2017Est. completion: Oct 2021194 patients
Phase 4Completed
NCT02991872GSKBlood draw

A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children

Start: Dec 2016Est. completion: Mar 2017150 patients
Phase 4Completed
NCT00343278GSKValaciclovir Hydrochloride

Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets

Start: Jul 2005Est. completion: Aug 200518 patients
Phase 4Completed
NCT02545517GSKRabipur

A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.

Start: Oct 2015Est. completion: Dec 2022459 patients
Phase 3Completed
NCT02548078GSKGlaxoSmithKline

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children

Start: Nov 2015Est. completion: May 2017600 patients
Phase 2Completed
NCT01991561Syneos HealthLow dose of H5 VLP vaccine + Alhydrogel

Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.

Start: Jun 2013Est. completion: Nov 2014390 patients
Phase 2Completed
NCT01244867Syneos Health20 micrograms dose H5 VLP

Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine

Start: Nov 2010Est. completion: Sep 2011255 patients
Phase 2Completed
NCT04758962GSK1 µg CoV2 SAM

A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults

Start: Feb 2021Est. completion: Apr 202240 patients
Phase 1Completed
NCT02022163Syneos HealthLow dose of H7 VLP vaccine + Alhydrogel

Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.

Start: Dec 2013Est. completion: Dec 2014100 patients
Phase 1Completed
NCT05606198Plus TherapeuticsExposed to a SARS-CoV-2 infection

Post-COVID-19 Monitoring in Routine Health Insurance Data With Focus on Autoimmune Diseases (POINTED-AD)

Start: May 2022Est. completion: Jun 2023
N/ACompleted
NCT05074953Plus TherapeuticsExposed to a SARS-CoV-2 infection

Post-COVID-19 Monitoring in Routine Health Insurance Data

Start: Aug 2021Est. completion: Dec 2023
N/ACompleted
NCT00749580MSDSwitch NRTIs as a Backbone to Raltegravir

A Pilot,Raltegravir Versus NRTIs as a Backbone Switched From a Stable Boosted PI Regimen

Start: Nov 2008Est. completion: Jul 201146 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.